BioMarin said the Amicus acquisition closed in April, with Q3 the first quarter of combined results. It sees peak revenue of $1.4 billion for Gallifold and $1.2 billion for OpFolda. The company also noted pending FDA approval for Voxogo in hypochondroplasia.
BMRN · Biomarin Pharmaceutical Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Biomarin said revenue rose 60% since 2023, supported by rare-disease commercialization and a pipeline approaching major clinical catalysts.
Biomarin reported Q3 revenue growth of 32% and first-ever $1 billion total revenue while adding four pipeline assets. Management expects roughly $220 million of operating-expense synergies to be fully realized in 2028.
Biomarin Pharmaceutical Inc reported nine-month 2026 total revenues of 2,780.6 million versus 2,346.7 million in 2025, while third-quarter net loss widened to (122.8) million from (30.7) million.
Biomarin surpassed $1 billion in quarterly revenue for the first time, growing 32% year over year, but reduced full-year 2026 guidance to between $3.8 billion and $3.9 billion due to order timing and Middle East disruption.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. BioMarin reported Q2 2026 revenue up 20% year-over-year to $990 million and raised full-year 2026 guidance for total revenues, Voxzogo, and non-GAAP diluted EPS, driven by strong demand and initial contributions from the recently closed Amicus acquisition (Galafold and Pombiliti+Opfolda), while integration-related costs and higher interest expense pressured GAAP and non-GAAP earnings.
- + Q2 total revenue grew 20% Y/Y to $990 million with raised full-year 2026 guidance
- + Raised full-year 2026 Voxzogo revenue guidance to at least $1 billion on 14% Q2 Voxzogo growth
- + Galafold and Pombiliti+Opfolda peak revenue potential of $2.6 billion with ~$220M synergies fully realized in 2028
- + Submitted Voxzogo sNDA for hypochondroplasia with potential 2027 launch
- + Deleverage target pulled forward ~1 year to below 2.5x gross leverage by mid-2027
- − GAAP net income fell 81% Y/Y to $45M due to Amicus acquisition costs and higher interest expense
- − ~$200M annualized acquisition-related interest expense expected to weigh on near-term earnings
- − Discontinued BMN 401 development after failing an ENPP1 deficiency co-primary endpoint
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| children with achondroplasia in 58 countries around the world | 58 | as of the end of the third quarter of 2026 | — |
| Non-GAAP Diluted EPS non-GAAP | 2.18 | nine months ended September 30, 2026 | — |
|
|
|||
| Non-GAAP Income non-GAAP | $430M | nine months ended September 30, 2026 | — |
| Non-GAAP Income from Operations non-GAAP | 683M | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Non-GAAP Operating Margin % non-GAAP | 24.6% | nine months ended September 30, 2026 | — |
|
|
|||
| number of children treated with VOXZOGO globally | 17% | third quarter of 2026 | — |
| number of patients treated with GALAFOLD | 13% | third quarter of 2026 | — |
| number of patients treated with POMBILITI + OPFOLDA | 69% | third quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BMRN
this stock
Biomarin Pharmaceutical Inc
|
$11.90B | +3.3% | +17.6% | — | 7.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 34
BioMarin said the Amicus acquisition closed in April, with Q3 the first quarter of combined results. It sees peak revenue of $1.4 billion for Gallifold and $1.2 billion for OpFolda. The company also noted pending FDA approval for Voxogo in hypochondroplasia.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BMRN | +8.3% | +8.5% | +11.6% | +5.0% | +3.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +13.8% | +14.8% | +17.2% | +10.2% | -1.6% |